MA41586A - Oligomères antisens de la protéine tau et leurs utilisations - Google Patents
Oligomères antisens de la protéine tau et leurs utilisationsInfo
- Publication number
- MA41586A MA41586A MA041586A MA41586A MA41586A MA 41586 A MA41586 A MA 41586A MA 041586 A MA041586 A MA 041586A MA 41586 A MA41586 A MA 41586A MA 41586 A MA41586 A MA 41586A
- Authority
- MA
- Morocco
- Prior art keywords
- tau protein
- antisense oligomers
- oligomeric
- tau
- expression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
La présente invention concerne des composés oligomères (oligomères) qui ciblent l'arnm de tau dans une cellule, conduisant à une expression réduite de la protéine tau. La réduction de l'expression de la protéine tau est bénéfique pour le traitement de certains troubles médicaux, par exemple un trouble neurologique.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562112058P | 2015-02-04 | 2015-02-04 | |
US201562156684P | 2015-05-04 | 2015-05-04 | |
US201562237922P | 2015-10-06 | 2015-10-06 | |
US201562238941P | 2015-10-08 | 2015-10-08 | |
US201662279612P | 2016-01-15 | 2016-01-15 | |
US201662279610P | 2016-01-15 | 2016-01-15 | |
US201662279614P | 2016-01-15 | 2016-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41586A true MA41586A (fr) | 2017-12-13 |
Family
ID=55443327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041586A MA41586A (fr) | 2015-02-04 | 2016-02-04 | Oligomères antisens de la protéine tau et leurs utilisations |
Country Status (24)
Country | Link |
---|---|
US (3) | US10799523B2 (fr) |
EP (2) | EP3253875B1 (fr) |
JP (1) | JP2018505676A (fr) |
KR (1) | KR20180016970A (fr) |
CN (1) | CN107922946A (fr) |
AU (1) | AU2016215155A1 (fr) |
BR (1) | BR112017016663A2 (fr) |
CA (1) | CA2975525A1 (fr) |
CL (1) | CL2017001956A1 (fr) |
CO (1) | CO2017009008A2 (fr) |
CR (1) | CR20170359A (fr) |
DK (1) | DK3253875T3 (fr) |
HK (1) | HK1248276A1 (fr) |
IL (1) | IL253730A0 (fr) |
MA (1) | MA41586A (fr) |
MX (1) | MX2017010066A (fr) |
PE (1) | PE20171766A1 (fr) |
PH (1) | PH12017550069A1 (fr) |
RU (1) | RU2017127609A (fr) |
SG (1) | SG11201706293XA (fr) |
TW (1) | TW201641691A (fr) |
UY (1) | UY36550A (fr) |
WO (1) | WO2016126995A1 (fr) |
ZA (1) | ZA201705119B (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5998326B2 (ja) | 2009-07-06 | 2016-09-28 | ウェイブ ライフ サイエンス リミテッドWave Life Sciences Ltd. | 新規核酸プロドラッグおよびその使用方法 |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
EP3248982A1 (fr) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Reactifs de type thiosulfonate pour la synthèse d'acides nucléiques fonctionnalisés |
WO2013148283A1 (fr) | 2012-03-30 | 2013-10-03 | Isis Pharmaceuticals, Inc. | Compositions et procédés pour moduler l'expression de tau pour réduire les crises d'épilepsie et modifier un syndrome neurodégénératif |
SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
TWI657819B (zh) | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
WO2016127000A1 (fr) | 2015-02-04 | 2016-08-11 | Bristol-Myers Squibb Company | Procédés de sélection de molécules thérapeutiques |
JOP20200228A1 (ar) * | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
JP7292204B2 (ja) * | 2016-12-01 | 2023-06-16 | サンガモ セラピューティクス, インコーポレイテッド | タウモジュレーターならびにその送達のための方法および組成物 |
US20200362347A1 (en) * | 2018-01-12 | 2020-11-19 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
EP3749766A1 (fr) * | 2018-02-09 | 2020-12-16 | F.Hoffmann-La Roche Ag | Oligonucléotides pour moduler l'expression de tmem106b |
JP7317029B2 (ja) | 2018-02-12 | 2023-07-28 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | 修飾化合物及びその使用 |
JP2021515784A (ja) * | 2018-03-13 | 2021-06-24 | ヤンセン ファーマシューティカ エヌ.ベー. | 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法 |
JP7434171B2 (ja) | 2018-04-13 | 2024-02-20 | ブリストル-マイヤーズ スクイブ カンパニー | 新規リン(v)系試薬、その製造方法、および立体選択的有機リン酸(v)化合物の製造における使用 |
WO2019233921A1 (fr) | 2018-06-05 | 2019-12-12 | F. Hoffmann-La Roche Ag | Oligonucléotides destinés à moduler l'expression de atxn2 |
JP7102557B2 (ja) * | 2018-07-03 | 2022-07-19 | エフ.ホフマン-ラ ロシュ アーゲー | Tau発現調節用オリゴヌクレオチド |
US20220213484A1 (en) * | 2019-04-03 | 2022-07-07 | Bristol-Myers Squibb Company | Angptl2 antisense oligonucleotides and uses thereof |
US11286485B2 (en) | 2019-04-04 | 2022-03-29 | Hoffmann-La Roche Inc. | Oligonucleotides for modulating ATXN2 expression |
JP7499267B2 (ja) | 2019-04-04 | 2024-06-13 | エフ. ホフマン-ラ ロシュ アーゲー | Atxn2発現を調節するためのオリゴヌクレオチド |
WO2020245233A1 (fr) | 2019-06-06 | 2020-12-10 | F. Hoffmann-La Roche Ag | Oligonucléotides antisens ciblant l'atxn3 |
WO2021055493A1 (fr) * | 2019-09-17 | 2021-03-25 | Zynerba Pharmaceuticals, Inc. | Traitement de l'encéphalopathie syngap1 |
US20230212572A1 (en) | 2020-06-09 | 2023-07-06 | Roche Innovation Center Copenhagen A/S | Guanosine Analogues for Use in Therapeutics Polynucleotides |
US20220177883A1 (en) | 2020-12-03 | 2022-06-09 | Hoffmann-La Roche Inc. | Antisense Oligonucleotides Targeting ATXN3 |
AR124227A1 (es) | 2020-12-03 | 2023-03-01 | Hoffmann La Roche | Oligonucleótidos antisentido que actúan sobre atxn3 |
AR124302A1 (es) * | 2020-12-11 | 2023-03-15 | Eisai R&D Man Co Ltd | Gápmeros de oligonucleótidos de objetivo tau |
EP4294925A1 (fr) * | 2021-02-17 | 2023-12-27 | Q-State Biosciences, Inc. | Agents thérapeutiques anti-sens de ube3a |
US20240279656A1 (en) * | 2021-06-29 | 2024-08-22 | Shape Therapeutics Inc. | Engineered Guide RNAs and Polynucleotides |
WO2023217437A1 (fr) * | 2022-05-13 | 2023-11-16 | Julius-Maximilians-Universität Würzburg | Procédé et molécules pour réduire l'accumulation de protéine tau axonale par blocage du transport d'arnm de cartographie médiée par hnrnp r pour le traitement de la maladie d'alzheimer |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5264423A (en) * | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
US5453491A (en) | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
CA2405246A1 (fr) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees |
US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
EP0580751A1 (fr) | 1991-04-19 | 1994-02-02 | Schering Corporation | Sous-unite du recepteur de l'interleukine-3 humaine |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
ATE242809T1 (de) | 1995-09-08 | 2003-06-15 | Genentech Inc | Vegf-verwandtes protein |
EP0922102B1 (fr) | 1996-07-03 | 2010-04-21 | Genentech, Inc. | Agonistes de recepteur du facteur de croissance des hepatocytes et utilisation desdits agonistes |
US6159462A (en) | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
GB9812127D0 (en) | 1998-06-06 | 1998-08-05 | Univ Glasgow | Detection of neural activity |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
EP1141017B1 (fr) | 1998-12-30 | 2008-09-10 | Beth Israel Deaconess Medical Center, Inc. | Caracterisation d'une famille de canaux calciques |
JP3971108B2 (ja) | 1999-01-06 | 2007-09-05 | ジェネンテック・インコーポレーテッド | インシュリン様成長因子(igf)i突然変異体 |
WO2000040612A1 (fr) | 1999-01-06 | 2000-07-13 | Genentech, Inc. | Variants mutants du facteur de croissance i semblable a l'insuline (igf) |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
DE60320258T2 (de) * | 2002-07-12 | 2009-06-25 | Axon Neuroscience Forschungs- Und Entwicklungs Gmbh | Transgenes tier welches das trunkierte alzheimer tau protein exprimiert |
DK3222722T3 (da) * | 2002-11-18 | 2019-06-17 | Roche Innovation Ct Copenhagen As | Antisense-design |
CA2515644A1 (fr) | 2003-02-10 | 2004-08-19 | Santaris Pharma A/S | Composes oligomeriques destines a la modulation de l'expression de ras |
US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
EP2397563A3 (fr) | 2004-09-17 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
WO2007031091A2 (fr) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Composes antagonistes d'arn de modulation de l'expression de p21 ras |
ES2516815T3 (es) | 2006-01-27 | 2014-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6 |
CN103554205A (zh) | 2006-05-05 | 2014-02-05 | Isis制药公司 | 调节gccr的表达的化合物和方法 |
CA2651453C (fr) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | Analogues d'acides nucleiques bicycliques modifies en 5' |
ES2377327T5 (es) * | 2006-10-18 | 2020-04-28 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
WO2008113832A2 (fr) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Composés arn antagonistes courts pour la modulation de l'arnm cible |
AU2008260277C1 (en) | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
WO2008154401A2 (fr) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Analogues d'acide nucléique bicyclique carbocylique |
ES2376507T5 (es) | 2007-07-05 | 2015-08-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos 6-disustituidos |
US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
WO2009090182A1 (fr) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | Oligonucléotides de type « gapmère » de nucléotide d'adn substitué en c4' |
WO2009100320A2 (fr) | 2008-02-07 | 2009-08-13 | Isis Pharmaceuticals, Inc. | Analogues d’acides nucléiques de cyclohexitol bicycliques |
US9290534B2 (en) | 2008-04-04 | 2016-03-22 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside |
WO2009124295A2 (fr) | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Composés oligomères comprenant des nucléosides bicycliques et ayant une toxicité réduite |
DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
CN101812127B (zh) * | 2009-02-19 | 2013-03-06 | 中国科学技术大学 | 微管结合蛋白及其编码基因与应用 |
US20100275274A1 (en) * | 2009-04-28 | 2010-10-28 | National Yang-Ming University | Mouse model for depression, schizophrenia and alzheimer's disease |
EP2462153B1 (fr) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Analogues d'acides nucléiques cyclohexoses bicycliques |
US9364495B2 (en) | 2009-10-20 | 2016-06-14 | Roche Innovation Center Copenhagen A/S | Oral delivery of therapeutically effective LNA oligonucleotides |
US8779118B2 (en) | 2010-01-11 | 2014-07-15 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
US9193752B2 (en) | 2010-03-17 | 2015-11-24 | Isis Pharmaceuticals, Inc. | 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
US9014425B2 (en) | 2010-04-21 | 2015-04-21 | Optosecurity Inc. | Method and system for use in performing security screening |
EP2673361B1 (fr) | 2011-02-08 | 2016-04-13 | Ionis Pharmaceuticals, Inc. | Composés oligomères comprenant des nucléotides bicycliques et leurs utilisations |
US8778884B2 (en) | 2011-05-26 | 2014-07-15 | Fondazione Salvatore Maugeri Clinica del Lavora e Della Riabilitazione | Glioprotectant peptide for use in the treatment of amyotrophic lateral sclerosis (ALS) and methods related thereto |
US9243291B1 (en) | 2011-12-01 | 2016-01-26 | Isis Pharmaceuticals, Inc. | Methods of predicting toxicity |
WO2013148283A1 (fr) | 2012-03-30 | 2013-10-03 | Isis Pharmaceuticals, Inc. | Compositions et procédés pour moduler l'expression de tau pour réduire les crises d'épilepsie et modifier un syndrome neurodégénératif |
EP3336189A1 (fr) | 2012-04-20 | 2018-06-20 | Ionis Pharmaceuticals, Inc. | Composés oligomères comprenant des nucléotides bicycliques et leurs utilisations |
EP4144845B1 (fr) | 2012-10-12 | 2024-04-24 | Ionis Pharmaceuticals, Inc. | Composés antisens et leurs utilisations |
US9695239B2 (en) * | 2012-10-24 | 2017-07-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Microtubule-modifying compound |
US9014359B1 (en) | 2013-01-11 | 2015-04-21 | Time Warner Cable Enterprises Llc | Generation of phone number lists and call filtering |
JP6629716B2 (ja) | 2013-03-14 | 2020-01-15 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | タウ発現を調節するための組成物および方法 |
WO2015006705A2 (fr) | 2013-07-11 | 2015-01-15 | The Trustees Of Columbia University In The City Of New York | Microarn assurant le silençage de l'expression de la protéine tau |
TWI657819B (zh) * | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
WO2016019063A1 (fr) | 2014-07-29 | 2016-02-04 | Isis Pharmaceuticals, Inc. | Compositions et méthodes pour moduler l'expression de tau |
JP6350987B2 (ja) | 2014-08-04 | 2018-07-04 | 本田技研工業株式会社 | GHファミリー3に属する耐熱性β―キシロシダーゼ |
-
2016
- 2016-02-04 MA MA041586A patent/MA41586A/fr unknown
- 2016-02-04 CR CR20170359A patent/CR20170359A/es unknown
- 2016-02-04 CN CN201680019681.3A patent/CN107922946A/zh active Pending
- 2016-02-04 EP EP16706943.4A patent/EP3253875B1/fr active Active
- 2016-02-04 AU AU2016215155A patent/AU2016215155A1/en not_active Abandoned
- 2016-02-04 US US15/016,169 patent/US10799523B2/en active Active
- 2016-02-04 RU RU2017127609A patent/RU2017127609A/ru not_active Application Discontinuation
- 2016-02-04 MX MX2017010066A patent/MX2017010066A/es unknown
- 2016-02-04 CA CA2975525A patent/CA2975525A1/fr not_active Abandoned
- 2016-02-04 PE PE2017001323A patent/PE20171766A1/es unknown
- 2016-02-04 DK DK16706943.4T patent/DK3253875T3/da active
- 2016-02-04 TW TW105103800A patent/TW201641691A/zh unknown
- 2016-02-04 KR KR1020177024109A patent/KR20180016970A/ko unknown
- 2016-02-04 EP EP19214990.4A patent/EP3653712B1/fr active Active
- 2016-02-04 BR BR112017016663A patent/BR112017016663A2/pt not_active Application Discontinuation
- 2016-02-04 JP JP2017541089A patent/JP2018505676A/ja active Pending
- 2016-02-04 US US15/549,021 patent/US11077132B2/en active Active
- 2016-02-04 SG SG11201706293XA patent/SG11201706293XA/en unknown
- 2016-02-04 UY UY0001036550A patent/UY36550A/es unknown
- 2016-02-04 WO PCT/US2016/016646 patent/WO2016126995A1/fr active Application Filing
-
2017
- 2017-07-27 ZA ZA2017/05119A patent/ZA201705119B/en unknown
- 2017-07-30 IL IL253730A patent/IL253730A0/en unknown
- 2017-08-01 CL CL2017001956A patent/CL2017001956A1/es unknown
- 2017-08-03 PH PH12017550069A patent/PH12017550069A1/en unknown
- 2017-09-01 CO CONC2017/0009008A patent/CO2017009008A2/es unknown
-
2018
- 2018-06-12 HK HK18107636.5A patent/HK1248276A1/zh unknown
-
2021
- 2021-07-02 US US17/367,242 patent/US20220143064A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3253875B1 (fr) | 2020-01-08 |
DK3253875T3 (da) | 2020-04-14 |
US20220143064A1 (en) | 2022-05-12 |
CR20170359A (es) | 2017-11-24 |
RU2017127609A (ru) | 2019-03-04 |
IL253730A0 (en) | 2017-09-28 |
TW201641691A (zh) | 2016-12-01 |
US11077132B2 (en) | 2021-08-03 |
US10799523B2 (en) | 2020-10-13 |
PH12017550069A1 (en) | 2018-02-05 |
CN107922946A (zh) | 2018-04-17 |
US20180161356A1 (en) | 2018-06-14 |
WO2016126995A1 (fr) | 2016-08-11 |
MX2017010066A (es) | 2017-11-01 |
UY36550A (es) | 2016-08-31 |
CL2017001956A1 (es) | 2018-06-01 |
SG11201706293XA (en) | 2017-09-28 |
EP3653712B1 (fr) | 2022-11-30 |
US20160237427A1 (en) | 2016-08-18 |
AU2016215155A1 (en) | 2017-08-17 |
ZA201705119B (en) | 2020-01-29 |
KR20180016970A (ko) | 2018-02-20 |
JP2018505676A (ja) | 2018-03-01 |
CO2017009008A2 (es) | 2017-11-21 |
EP3253875A1 (fr) | 2017-12-13 |
PE20171766A1 (es) | 2017-12-21 |
CA2975525A1 (fr) | 2016-08-11 |
BR112017016663A2 (pt) | 2018-04-10 |
HK1248276A1 (zh) | 2018-10-12 |
EP3653712A1 (fr) | 2020-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41586A (fr) | Oligomères antisens de la protéine tau et leurs utilisations | |
PH12020500622A1 (en) | 17á-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
MA43335A (fr) | Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr | |
EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
TN2019000126A1 (fr) | Nouvelles compositions antivirales pour le traitement des infections liées aux coronavirus. | |
EA201792263A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
MA39219B1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
MA44426B1 (fr) | Compositions et méthodes pour diminier l'expression de tau | |
MA41977B1 (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
MA43113A (fr) | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci | |
MA41758A (fr) | Procédés de traitement de l'infertilité | |
MA39170B1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
MA46548A (fr) | Fsh pour le traitement de l'infertilité | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
EA202090555A1 (ru) | Фармацевтические композиции, содержащие антитела к бета-амилоиду | |
MA35457B1 (fr) | Nouvelles formulations de pyriméthanil et leur utilisations dans le traitement des cultures | |
MA38678A1 (fr) | Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués | |
WO2020060987A8 (fr) | Compositions d'arni de composant du complément c5 et leurs procédés d'utilisation | |
MA39230B1 (fr) | Hexahydrofuropyrroles utilisés comme inhibiteurs de pde1 | |
FR3074421B1 (fr) | Extrait d'helichrysum gymnocephalum pour le traitement et/ou la prevention des dermatoses inflammatoires | |
MA38717A1 (fr) | Oligomères antisens et conjugués ciblant pcsk9 | |
MA62937B1 (fr) | Compositions d'arni d'angiotensinogène (agt) et leurs procédés d'utilisation | |
MA55892B1 (fr) | Phénylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation | |
MA51297B1 (fr) | Quinazolinones en tant qu'inhibiteurs de parp14 | |
FR3055895B1 (fr) | Procede de separation de l'uranium utilisant une hydroxyapatite dopee au cuivre, procede de preparation d'une telle hydroxyapatite et hydroxyapatite ainsi preparee. |